Willow Biosciences and SUANFARMA Collaborate on Large-Volume Anti-Infective API Development through Precision Fermentation

Willow Biosciences Inc. and SUANFARMA have announced a collaboration agreement for the development of a large-volume anti-infective Active Pharmaceutical Ingredient (API) through precision fermentation. This partnership aims to optimize cell line productivity and create a more cost-effective production process for the API.

Under the agreement, SUANFARMA will have access to Willow’s proprietary strain optimization technologies, which will enable the development of a sustainable and efficient manufacturing process at SUANFARMA’s European manufacturing site. By leveraging Willow’s expertise in strain engineering, both companies aim to produce key products that promote better human health and wellness.

Chris Savile, President & CEO of Willow Biosciences, expressed his enthusiasm for expanding the successful relationship with SUANFARMA. He highlighted the joint capabilities and efficient manufacturing resources that will be utilized to bring sustainably sourced products to the market.

Daniel Rivero, Industrial Director of SUANFARMA, emphasized the potential of fermentation technology to maximize product quality while reducing costs. He mentioned the intention to bring life-enhancing products to the market at an industrial scale through their manufacturing site in Europe.

This collaboration builds upon the existing alliance between Willow and SUANFARMA, which was announced earlier this year. The companies have been working together on synthetic molecules, including anti-infectives and other APIs, as well as intermediates for the pharmaceutical and biotech industries. The current collaboration marks further progress in broadening their relationship by offering an end-to-end synthetic biology solution and expanding their joint product portfolio.

Willow Biosciences specializes in developing and producing precision fermented functional ingredients for various industries, including health and wellness, food and beverage, and personal care. Their FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability as a core focus.

SUANFARMA, founded in 1993, is a B2B life science partner that specializes in the development, production, and commercialization of ingredients for the pharmaceutical, veterinary, and nutraceutical industries. With a strong global commercial network, SUANFARMA serves over 3,000 active customers in more than 70 countries.

The collaboration between Willow Biosciences and SUANFARMA demonstrates their commitment to innovation and advancing the production of essential pharmaceutical ingredients. By leveraging precision fermentation and strain engineering technologies, they aim to create a more sustainable and cost-effective approach to manufacturing anti-infective APIs.